David P Schenkein insider trades
Open-market stock purchases and sales by David P Schenkein, Director at Prime Medicine, Inc, from SEC Form 4 filings since Sep 30, 2013.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging -37%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 5, 2026 | PRME Prime Medicine, Inc | Bought (not open market) | — |
| Jun 3, 2026 | DNLI Denali Therapeutics Inc | Bought (not open market) | — |
| Jun 3, 2026 | DNLI Denali Therapeutics Inc | Bought (not open market) | — |
| Jan 2, 2026 | REGN Regeneron Pharmaceuticals, Inc | Bought (not open market) | — |
| Jan 2, 2026 | REGN Regeneron Pharmaceuticals, Inc | Bought (not open market) | — |
Companies traded
- PRME Prime Medicine, Inc: other filings, last Jun 5, 2026
- DNLI Denali Therapeutics Inc: 7 sales, last Jun 3, 2026
- REGN Regeneron Pharmaceuticals, Inc: other filings, last Jan 2, 2026
- AGIO Agios Pharmaceuticals, Inc: 1 buy, 91 sales, last Jun 20, 2024
- BLUE bluebird bio, Inc: 1 buy, 2 sales, last Jun 18, 2020
- FMI Foundation Medicine, Inc: other filings, last Jun 16, 2016